Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12

Beverly E. Sha, Michelle Onorato, John A. Bartlett, Ronald J. Bosch, Evgenia Aga, Mostafa Nokta, Elizabeth M. Adams, Xiao Dong Li, John Eldridge, Richard B Pollard

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We examined the safety and immunogenicity of a human leukocyte antigen-based HIV envelope polyvalent synthetic peptide vaccine, C4-V3, alone and in combination with subcutaneous IL-12 in nine HIV-infected patients. Lymphocyte proliferative responses increased threefold or more to all four peptides at two consecutive post-immunization timepoints for four individuals. Three responders had received IL-12, suggesting a possible adjuvant effect of IL-12. Transient mild injection site reactions (7/9) and systemic symptoms (3/9) occurred.

Original languageEnglish (US)
Pages (from-to)1203-1206
Number of pages4
JournalAIDS
Volume18
Issue number8
DOIs
StatePublished - May 21 2004

Fingerprint

AIDS Vaccines
Interleukin-12
Safety
Peptides
HIV
Synthetic Vaccines
Subunit Vaccines
HLA Antigens
Immunization
Lymphocytes
Injections

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. / Sha, Beverly E.; Onorato, Michelle; Bartlett, John A.; Bosch, Ronald J.; Aga, Evgenia; Nokta, Mostafa; Adams, Elizabeth M.; Li, Xiao Dong; Eldridge, John; Pollard, Richard B.

In: AIDS, Vol. 18, No. 8, 21.05.2004, p. 1203-1206.

Research output: Contribution to journalArticle

Sha, BE, Onorato, M, Bartlett, JA, Bosch, RJ, Aga, E, Nokta, M, Adams, EM, Li, XD, Eldridge, J & Pollard, RB 2004, 'Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12', AIDS, vol. 18, no. 8, pp. 1203-1206. https://doi.org/10.1097/00002030-200405210-00015
Sha BE, Onorato M, Bartlett JA, Bosch RJ, Aga E, Nokta M et al. Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS. 2004 May 21;18(8):1203-1206. https://doi.org/10.1097/00002030-200405210-00015
Sha, Beverly E. ; Onorato, Michelle ; Bartlett, John A. ; Bosch, Ronald J. ; Aga, Evgenia ; Nokta, Mostafa ; Adams, Elizabeth M. ; Li, Xiao Dong ; Eldridge, John ; Pollard, Richard B. / Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. In: AIDS. 2004 ; Vol. 18, No. 8. pp. 1203-1206.
@article{32836eecdaaa47c7a997b5e6a9e6ea73,
title = "Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12",
abstract = "We examined the safety and immunogenicity of a human leukocyte antigen-based HIV envelope polyvalent synthetic peptide vaccine, C4-V3, alone and in combination with subcutaneous IL-12 in nine HIV-infected patients. Lymphocyte proliferative responses increased threefold or more to all four peptides at two consecutive post-immunization timepoints for four individuals. Three responders had received IL-12, suggesting a possible adjuvant effect of IL-12. Transient mild injection site reactions (7/9) and systemic symptoms (3/9) occurred.",
author = "Sha, {Beverly E.} and Michelle Onorato and Bartlett, {John A.} and Bosch, {Ronald J.} and Evgenia Aga and Mostafa Nokta and Adams, {Elizabeth M.} and Li, {Xiao Dong} and John Eldridge and Pollard, {Richard B}",
year = "2004",
month = "5",
day = "21",
doi = "10.1097/00002030-200405210-00015",
language = "English (US)",
volume = "18",
pages = "1203--1206",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12

AU - Sha, Beverly E.

AU - Onorato, Michelle

AU - Bartlett, John A.

AU - Bosch, Ronald J.

AU - Aga, Evgenia

AU - Nokta, Mostafa

AU - Adams, Elizabeth M.

AU - Li, Xiao Dong

AU - Eldridge, John

AU - Pollard, Richard B

PY - 2004/5/21

Y1 - 2004/5/21

N2 - We examined the safety and immunogenicity of a human leukocyte antigen-based HIV envelope polyvalent synthetic peptide vaccine, C4-V3, alone and in combination with subcutaneous IL-12 in nine HIV-infected patients. Lymphocyte proliferative responses increased threefold or more to all four peptides at two consecutive post-immunization timepoints for four individuals. Three responders had received IL-12, suggesting a possible adjuvant effect of IL-12. Transient mild injection site reactions (7/9) and systemic symptoms (3/9) occurred.

AB - We examined the safety and immunogenicity of a human leukocyte antigen-based HIV envelope polyvalent synthetic peptide vaccine, C4-V3, alone and in combination with subcutaneous IL-12 in nine HIV-infected patients. Lymphocyte proliferative responses increased threefold or more to all four peptides at two consecutive post-immunization timepoints for four individuals. Three responders had received IL-12, suggesting a possible adjuvant effect of IL-12. Transient mild injection site reactions (7/9) and systemic symptoms (3/9) occurred.

UR - http://www.scopus.com/inward/record.url?scp=2942627435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942627435&partnerID=8YFLogxK

U2 - 10.1097/00002030-200405210-00015

DO - 10.1097/00002030-200405210-00015

M3 - Article

VL - 18

SP - 1203

EP - 1206

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 8

ER -